NCT03254667View on ClinicalTrials.gov

LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis

Enrolling by invitationOBSERVATIONAL
Enrollment

3,500

Participants

Timeline

Start Date

July 25, 2017

Primary Completion Date

November 10, 2030

Study Completion Date

November 30, 2031

Conditions
Psoriasis
Interventions
BIOLOGICAL

Brodalumab

Brodalumab

DRUG

Comparator Drug (non-biologic IL-17 inhibitors)

Comparator subjects treated with non-biologic IL-17 inhibitors

Trial Locations (1)

08807

Registry, Bridgewater

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03254667 - LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis | Biotech Hunter | Biotech Hunter